Analysts have clear opinions on SGMO.

There are 3 analysts on the Wall offering 12 month price targets for Sangamo Biosciences in the last 3 months. The average price target is $13.50 with a high forecast of $16.00 and a low forecast of $11.00. The average price target represents a 53.58% increase from the last price of $8.79.
Sangamo Therapeutics, Inc. (SGMO) is followed by 3 analysts on the street.

Debjit Chattopadhyay from H.C. Wainwright rates it a Buy with a target of $16.00.

Similarly, 24 days ago Ritu Baral of Cowen & Co. Reiterated a Buy with a target of —.

The consensus on the street is Moderate Buy.

What does Sangamo Therapeutics, Inc.(SGMO) do ?
Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Sangamo Therapeutics, Inc. (SGMO) Insider Trades

Multiple company employees have indulged in significant insider trading. Sangamo Therapeutics, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

EVP, CFO, Yi Kathy : S – Sale+OE(-$50,000) of SGMO in the trading session of 2019-05-15.

EVP, CFO Yi Kathy : S – Sale+OE(-$60,550) of SGMO in the trading session of 2019-04-15.

EVP, CFO Yi Kathy : S – Sale+OE(-$50,000) of Sangamo Therapeutics, Inc. in the trading session of 2019-03-15.

Looking for stocks just like SGMO?

Based on Wall Street analyst research, several stocks are similar to SGMO
They are:
– RHHBY [Info can be found here: ]
– LGND [Info can be found here: ]
– RGNX [Info can be found here: ]